EGFR and melanoma: The importance of placing mutations in the context of their gene expression has been illuminated recently by Prahallad and colleagues [2], who established the therapeutic effect of PLX4032 against the BRAF V600E oncoprotein, which is mechanistically linked to the activation of EGFR. Thus, differential expression of EGFR in different cell types (colon cancers versus melanomas) has a dramatic impact on drug efficacy.